Recent progress in the design of small molecule inhibitors of HIV RNase H

Current Pharmaceutical Design

Volumn 12, Issue 15, 2006, Pages 1909-1922

  Klumpp, Klaus ^a   Mirzadegan, Tara ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

Diketoacids; N hydroxyimides; Phosphodiester hydrolysis; Primer binding site (PBS); Sesquiterpenoid quinones

Indexed keywords

ANTIRETROVIRUS AGENT; AVAROL; AVARONE; ILLIMAQUINONE; MAPPICINE DERIVATIVE; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; N (4 TERT BUTYLBENZOYL) 2 HYDROXY 1 NAPHTHALDEHYDE HYDRAZONE; N ETHYLMALEIMIDE; NAPHTHOQUINONE; NEVIRAPINE; PD 126338; RDS 1643; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SESQUITERPENE DERIVATIVE; THUJAPLICIN; THUJAPLICINOL; UNCLASSIFIED DRUG; ZIDOVUDINE DERIVATIVE;

ANTIVIRAL ACTIVITY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROLYSIS; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS STRAIN;

BINDING SITES; DRUG DESIGN; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN SUBUNITS; REVERSE TRANSCRIPTASE INHIBITORS; RIBONUCLEASE H, CALF THYMUS;

EID: 33646497669     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776873653     Document Type: Review

References (86)

1. Freed EO, Martin MA. In: Knipe D, Howley P (ed.), HIVs and their replication. Fields Virology, Lippincott Williams & Wilkins, Philadelphia, PA, 2001; pp. 1971-2042.
2. Telesnitsky A, Goff SP. In: Coffin JM, Hughes SH, Varmus HE (ed.). Reverse transcription and the generation of viral DNA. Retroviruses, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, NY, 1997; pp. 121-160.
3. Schatz O, Cromme FV, Nass T, Lindemann D. In: Papas TS (ed.), Gene Regulation and AIDS: Transcritpional Activation, Retroviruses and Pathogenesis, Gulf Publishing Company, Houston, TX, 1989.
4. Tisdale M, Schulze T, Larder BA, Moelling K. Mutations within the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase abolish virus infectivity. J Gen Virol 1991; 72: 59-66.
5. Andreola ML, De Soultrait VR, Fournier M, Parissi V, Desjobert C, Litvak S. HIV-1 integrase and RNase H activities as therapeutic targets. Expert Opin Ther Targets 2002; 6: 433-446.
6. Klarmann GJ, Hawkins ME, Le Grice SFJ. Uncovering the complexities of retroviral ribonuclease H reveals its potential as a therapeutic target. AIDS Rev 2002; 4: 183-194.
7. Tarrago-Litvak L, Andreola ML, Fournier M, Nevinsky A, Parissi V, De Soultrait VR, et al. Inhibitors of HIV-1 reverse transcriptase and integrase: classical and emerging therapeutical approaches. Curr Pharm Des 2002; 8: 595-614.
8. Davies JF 2nd, Hostomska Z, Hostomsky Z, Jordan SR, Matthews DA. Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase. Science 1991; 252: 88-95.
9. Jacobo-Molina A, Ding J, Nanni RG, Clark AD Jr, Lu X, Tantillo C, et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci USA 1993; 90: 6320-6324.
10. Huang H, Chopra R, Verdine GL, Harrison SC. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 1998; 282: 1669-1675.
11. Sarafianos SG, Das K, Tantillo C, Clark AD Jr, Ding J, Whitcomb JM, et al . Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA. EMBO J 2001; 20: 1449-1461.
12. Pari K, Mueller GA, DeRose EF, Kirby TW, London RE. Solution structure of the RNase H domain of the HIV-1 reverse transcriptase in the presence of magnesium. Biochemistry 2003; 42: 639-650.
13. Yang W, Hendrickson WA, Crouch RJ, Satow Y. Structure of ribonuclease H phased at 2 A resolution by MAD analysis of the selenomethionyl protein. Science 1990; 249: 1398-1405.
14. Katayanagi K, Miyagawa M, Matsushima M, Ishikawa M, Kanaya S, Ikehara M, et al. Three-dimensional structure of ribonuclease H from E. coli. Nature 1990; 347: 306-309.
15. Keck JL, Marqusee S. Substitution of a highly basic helix/loop sequence into the RNase H domain of human immunodeficiency virus reverse transcriptase restores its Mn(2+)-dependent RNase H activity. Proc Natl Acad Sci USA 1995; 92: 2740-2744.
16. Yang W, Steitz TA. Recombining the structures of HIV integrase, RuvC and RNase H. Structure 1995; 3: 131-134.
17. Wohrl BM, Volkmann S, Moelling K. Mutations of a conserved residue within HIV-1 ribonuclease H affect its exo- and endonuclease activities. J Mol Biol 1991; 220: 801-818.
18. Rausch JW, Le Grice SF. Substituting a conserved residue of the ribonuclease H domain alters substrate hydrolysis by retroviral reverse transcriptase. J Biol Chem 1997; 272: 8602-8610.
19. Hang JQ, Rajendran S, Yang Y, Li Y, Wong Kai In P, Overton H, et al. Activity of the isolated HIV RNase H domain and specific inhibition by N-hydroxyimides. Biochem Biophys Res Comm 2004; 317: 321-329.
20. Goedken ER, Raschke TM, Marqusee S. Importance of the C-terminal helix to the stability and enzymatic activity of Escherichia coli ribonuclease H. Biochemistry 1997; 36: 7256-7263.
21. Mueller GA, Pari K, DeRose EF, Kirby TW, London RE. Backbone dynamics of the RNase H domain of HIV-1 reverse transcriptase. Biochemistry 2004; 43: 9332-9342.
22. Hang JQ, Rajendran S, Yang Y, Li Y, Wong Kai In P, Overton H, et al. Intrinsic activity of the isolated HIV RNase H domain and inhibition by N-hydroxyimides. 17th International Conference on Antiviral Research (ICAR), Tucson, AZ, May 02-06. 2004.
23. Hansen J, Schulze T, Mellert W, Moelling K. Identification and characterization of HIV-specific RNase H by monoclonal antibody. EMBO J 1988; 7: 239-243.
24. Hostomsky Z, Hostomska Z, Hudson GO, Moomaw EW, Nodes BR. Reconstitution in vitro of RNase H activity by using purified N-terminal and C-terminal domains of human immunodeficiency virus type 1 reverse transcriptase. Proc Natl Acad Sci USA 1991; 88: 1148-1152.
25. Evans DB, Brawn K, Deibel MR Jr, Tarpley WG, Sharma SK. A recombinant ribonuclease H domain of HIV-1 reverse transcriptase that is enzymatically active. J Biol Chem 1991; 266: 20583-20585.
26. Stammers DK, Tisdale M, Court S, Parmar V, Bradley C, Ross CK. Rapid purification and characterisation of HIV-1 reverse transcriptase and RNase H engineered to incorporate a C-terminal tripeptide α-tubulin epitope. FEBS Lett 1991; 283: 298-302.
27. Smith JS, Roth MJ. Purification and characterization of an active human immunodeficiency virus type 1 RNase H domain. J Virol 1993; 67: 4037-4049.
28. Stahl SJ, Kaufman JD, Vikic-Topic S, Crouch RJ, Wingfield PT. Construction of an enzymatically active ribonuclease H domain of human immunodeficiency virus type 1 reverse transcriptase. Protein Eng 1994; 7: 1103-1108.
29. Gotte M, Fackler S, Hermann T, Perola E, Cellai L, Gross HJ, et al. HIV-1 reverse transcriptase-associated RNase H cleaves RNA/RNA in arrested complexes: implications for the mechanism by which RNase H discriminates between RNA/RNA and RNA/DNA. EMBO J 1995; 14: 833-841.
30. Raines RT. Ribonuclease A. Chem Rev 1998; 98: 1045-1066.
31. Weston SA, Lahm A, Suck D. X-ray structure of the DNase Id(GGTATACC)2 complex at 2.3 A resolution. J Mol Biol 1992; 226: 1237-1256.
32. Galburt EA, Stoddard BL. Catalytic mechanisms of restriction and homing endonucleases. Biochemistry 2002; 41: 13851-13860.
33. Lukacs CM, Kucera R, Schildkraut I, Aggarwal AK. Understanding the immutability of restriction enzymes: crystal structure of BglII and its DNA substrate at 1.5 A resolution. Nat Struct Biol 2000; 7: 134-140.
34. Miller MD, Cai J, Krause KL. The active site of Serratia endonuclease contains a conserved magnesium-water cluster. J Mol Biol 1999; 288: 975-987.
35. Tsunaka Y, Haruki M, Morikawa M, Oobatake M, Kanaya S. Dispensability of glutamic acid 48 and aspartic acid 134 for Mn2+-dependent activity of Escherichia coli ribonuclease HI. Biochemistry 2003; 42: 3366-3374.
36. Kashiwagi T, Jeanteur D, Haruki M, Katayanagi K, Kanaya S, Morikawa K. Proposal for new catalytic roles for two invariant residues in Escherichia coli ribonuclease HI. Protein Eng 1996; 9: 857-867.
37. Kanaya S, Oobatake M, Liu Y. Thermal stability of Escherichia coli ribonuclease HI and its active site mutants in the presence and absence of the Mg2+ ion. Proposal of a novel catalytic role for Glu48. J Biol Chem 1996; 271: 32729-32736.
38. Haruki M, Tsunaka Y, Morikawa M, Iwai S, Kanaya S. Catalysis by Escherichia coli ribonuclease HI is facilitated by a phosphate group of the substrate. Biochemistry 2000; 39: 13939-13944.
39. Katayanagi K, Okumura M, Morikawa K. Crystal structure of Escherichia coli RNase HI in complex with Mg2+ at 2.8 A resolution: proof for a single Mg(2+)-binding site. Proteins 1993; 17: 337-346.
40. Oda Y, Nakamura H, Kanaya S, Ikehara M. Binding of metal ions to E. coli RNase HI observed by 1H-15N heteronuclear 2D NMR. J Biomol NMR 1991; 1: 247-255.
41. Huang HW, Cowan JA. Metallobiochemistry of the magnesium ion. Characterization of the essential metal-binding site in Escherichia coli ribonuclease H. Eur J Biochem 1994; 219: 253-260.
42. Goedken ER, Marqusee S. Co-crystal of Escherichia coli RNase HI with Mn2+ ions reveals two divalent metals bound in the active site. J Biol Chem 2001; 276: 7266-7271.
43. Keck JL, Goedken ER, Marqusee S. Activation/attenuation model for RNase H. A one-metal mechanism with second-metal inhibition. J Biol Chem 1998; 273: 34128-34133.
44. Klumpp K, Hang JQ, Rajendran S, Yang Y, Derosier A, Wong Kai In P, et al. Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors. Nucleic Acids Res 2003; 31: 6852-6859.
45. Beese LS, Steitz TA. Structural basis for the 3′-5′ exonuclease activity of Escherichia coli DNA polymerase I: a two metal ion mechanism. EMBO J 1991; 10: 25-33.
46. Newman M, Lunnen K, Wilson G, Greci J, Schildkraut I, Phillips SE. Crystal structure of restriction endonuclease BglI bound to its interrupted DNA recognition sequence. EMBO J 1998; 17: 5466-5476.
47. Horton JR, Cheng X. PvuII endonuclease contains two calcium ions in active sites. J Mol Biol 2000; 300: 1049-1056.
48. Sun W, Pertzev A, Nicholson AW. Catalytic mechanism of Escherichia coli ribonuclease III: kinetic and inhibitor evidence for the involvement of two magnesium ions in RNA phosphodiester hydrolysis. Nucleic Acids Res 2005; 33: 807-815.
49. Tsunaka Y, Takano K, Matsumura H, Yamagata Y, Kanaya S. Identification of single Mn(2+) binding sites required for activation of the mutant proteins of E. coli RNase HI at Glu48 and/or Asp134 by X-ray crystallography. J Mol Biol 2005; 345: 1171-1183.
50. Doan L, Handa B, Roberts NA, Klumpp K. Metal ion catalysis of RNA cleavage by the influenza virus endonuclease. Biochemistry 1999; 38: 5612-5619.
51. Klumpp K, Hooker L, Handa B. Influenza virus endoribonuclease. Methods Enzymol 2001; 342: 451-466.
52. Pontius BW, Lott WB, von Hippel PH. Observations on catalysis by hammerhead ribozymes are consistent with a two-divalent-metalion mechanism. Proc Natl Acad Sci USA 1997; 94: 2290-2294.
53. Lott WB, Pontius BW, von Hippel PH. A two-metal ion mechanism operates in the hammerhead ribozyme-mediated cleavage of an RNA substrate. Proc Natl Acad Sci USA 1998; 95: 542-547.
54. Cowan JA, Ohyama T, Howard K, Rausch JW, Cowan SM, Le Grice SF. Metal-ion stoichiometry of the HIV-1 RT ribonuclease H domain: evidence for two mutually exclusive sites leads to new mechanistic insights on metal-mediated hydrolysis in nucleic acid biochemistry. J Biol Inorg Chem 2000; 5: 67-74.
55. Cristofaro JV, Rausch JW, Le Grice SF, DeStefano JJ. Mutations in the ribonuclease H active site of HIV-RT reveal a role for this site in stabilizing enzyme-primer-template binding. Biochemistry 2002; 41: 10968-10975.
56. Parkes KE, Ermert P, Fassler J, Ives J, Martin JA, Merrett JH, et al. Use of a pharmacophore model to discover a new class of influenza endonuclease inhibitors. J Med Chem 2003; 46: 1153-1164.
57. Tomassini J, Selnick H, Davies ME, Armstrong ME, Baldwin J, Bourgeois M, et al. Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2, 4-dioxobutanoic acid compounds. Antimicrob Agents Chemother 1994; 38: 2827-2837.
58. Shaw-Reid CA, Munshi V, Graham P, Wolfe A, Witmer M, Danzeisen R, et al. Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2, 4-dioxobutanoic acid. J Biol Chem 2003; 278: 2777-2780.
59. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287: 646-650
60. Summa V, Petrocchi A, Pace P, Matassa VG, De Francesco R, Altamura S, et al . Discovery of alpha, gamma-diketo acids as potent selective and reversible inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase. J Med Chem 2004; 47: 14-17.
61. Shaw-Reid CA, Feuston B, Munshi V, Getty K, Krueger J, Hazuda DJ, et al. Dissecting the Effects of DNA Polymerase and Ribonuclease H Inhibitor Combinations on HIV-1 Reverse-Transcriptase Activities. Biochemistry 2005; 44: 1595-1606.
62. Tramontano E, Esposito F, Badas R, Di Santo R, Costi R, La Colla P. 6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2, 4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro. Antiviral Res 2005; 65: 117-124.
63. Young SD, Wai JS, Embrey MW, Fisher TE. HIV integrase inhibitors. United Stated Patent US6262055B1 2001.
64. Loya S, Tal R, Kashman Y, Hizi A. Illimaquinone, a selective inhibitor of the RNase H activity of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1990; 34: 2009-2012.
65. Min BS, Miyashiro H, Hattori M. Inhibitory effects of quinones on RNase H activity associated with HIV-1 reverse transcriptase. Phytother Res 2002; 16: S57-S62.
66. Loya S, Hizi A. The inhibition of human immunodeficiency virus type 1 reverse transcriptase by avarol and avarone derivatives. FEBS Lett 1990; 269: 131-134.
67. Loya S, Hizi A. The interaction of illimaquinone, a selective inhibitor of the RNase H activity, with the reverse transcriptases of human immunodeficiency and murine leukemia retroviruses. J Biol Chem 1993; 268: 9323-9328.
68. Tan CK, Civil R, Mian AM, So AG, Downey KM. Inhibition of the RNase H activity of HIV reverse transcriptase by azidothymidylate. Biochemistry 1991; 30: 4831-4835.
69. Zhan X, Tan CK, Scott WA, Mian AM, Downey KM, So AG. Catalytically distinct conformations of the ribonuclease H of HIV-1 reverse transcriptase by substrate cleavage patterns and inhibition by azidothymidylate and N-ethylmaleimide. Biochemistry 1994; 33: 1366-1372.
70. Allen SJW, Krawczyk SH, McGee LR, Bischofberger N, Mulato AS, Cherrington JM. Inhibition of HIV-1 Rnase H activity by nucleotide dimers and monomers. Antivir Chem Chemother 1996; 7: 37-45.
71. Matthes E, von Jant-Lipinski M. New dinucleotide derivatives are RNase H inhibitors - useful for the treatment of HIV and HBV infections. German Patent DE19640054A 1998.
72. Borkow G, Fletcher RS, Barnard J, Arion D, Motakis D, Dmitrienko GI, et al. Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4-tertbutylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone. Biochemistry 1997; 36: 3179-3185.
73. Arion D, Sluis-Cremer N, Min KL, Abram ME, Fletcher RS, Parniak MA. Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase. Effects on ribonuclease H activity and inhibition of this activity by N-acylhydrazones. J Biol Chem 2002; 277: 1370-1374.
74. Sluis-Cremer N, Arion D, Parniak MA. Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors. Mol Pharmacol 2002; 62: 398-405.
75. Parniak MA. RNase H: Can selective inhibitors be identified? 12th Conference on Retroviruses and Opportunistic Infections (CROI) 2005; Abstract 114.
76. Himmel DM, Sarafianos SG, Clark AD Jr, Parniak MA, Hughes SH, Arnold E. Crystal structure of a complex of HIV-1 reverse transcriptase with an RNase H inhibitor bound at a novel site on the enzyme. 12th Conference on Retroviruses and Opportunistic Infections (CROI) 2005; Abstract 157.
77. Gabbara S, Davis WR, Hupe L, Hupe D, Peliska JA. Inhibitors of DNA strand transfer reactions catalyzed by HIV-1 reverse transcriptase. Biochemistry 1999; 38: 13070-13076.
78. Parniak MA, Min KL, Budihas SR, Le Grice SF, Beutler JA. A fluorescence-based high-throughput screening assay for inhibitors of human immunodeficiency virus-1 reverse transcriptase-associated ribonuclease H activity. Anal Biochem 2003; 322: 33-39.
79. Budihas SR, Gorshkova I, Gaidamakov S, Wamiru A, Bona MK, Parniak MA, et al. Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones. Nucleic Acids Res 2005; 33: 1249-1256.
80. Curran DP, Parniak MA, Gabarda A, Zhang W, Luo Z, Chen CHT. Mappicine analogs, intermediates in the synthesis of mappicine analogs and methods of synthesis of mappicine analogs. United States Patent Application Publication US2004/0077674 A1 2004.
81. Little S, Drusano G, Schooley RT, Haas D, Kumar P, Hammer SM, et al. Antiretroviral effect of L-00870810, a novel HIV-1 integrase inhibitor in HIV-1 infected patients. 12th Conference on Retroviruses and Opportunistic Infections (CROI) 2005; Abstract 161.
82. Dyda F, Hickman AB, Jenkins TM, Engelman A, Craigie R, Davies DR. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 1994; 266: 1981-1986.
83. Wilcox DE. Binuclear Metallohydrolases. Chem Rev 1996; 96: 2435-2458.
84. Andreola ML. Closely related antiretroviral agents as inhibitors of two HIV-1 enzymes, ribonuclease H and integrase: "killing two birds with one stone". Curr Pharm Des 2004; 10(30): 3713-23.
85. Barbaro G, Scozzafava A, Mastrolorenzo A, Supuran CT. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 2005; 11(14): 1805-43.
86. Spankuch B, Strebhardt K. RNA interference-based gene silencing in mice: the development of a novel therapeutical strategy. Curr Pharm Des 2005; 11(26): 3405-19.